Nasdaq · Healthcare
Black Diamond Therapeutics, Inc. (BDTX)
As-reported financials and recent SEC filings for Black Diamond Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$70.0M
Net income
$22.4M
Net margin
32.0%
Diluted EPS
$0.39
ROE
19.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $70.0M | $0 | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $12.5M | $-78.8M | $-86.5M | $-92.8M | $-126.9M |
| Net income | $22.4M | $-69.7M | $-82.4M | $-91.2M | $-125.6M |
| Diluted EPS | $0.39 | $-1.27 | $-1.88 | $-2.52 | $-3.47 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-29
View on EDGAR →42026-06-29
View on EDGAR →42026-06-29
View on EDGAR →42026-06-29
View on EDGAR →42026-06-29
View on EDGAR →42026-06-29
View on EDGAR →8-K2026-06-29
View on EDGAR →42026-06-22
View on EDGAR →Largest Healthcare peers
Go deeper on BDTX
Search Black Diamond Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.